Company intelligence / Profile preview

Wuhan Zhonglian Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Wuhan Zhonglian Pharmaceutical developed and commercialized a range of drugs including herbal medicines and small molecules. Several products have been approved in China since at least 1985; notable approvals include nicotinamide for pellagra, amantadine hydrochloride for influenza, QiangLiGanMao for fever, dilazep hydrochloride hydrate for myocardial ischemia, and BiYanPian for rhinitis. The company was acquired by Sinopharm/China TCM and is now dissolved as an independent entity.

Therapeutic areas: CardiovascularImmunologyMetabolic DisordersInfectious Diseases
Modalities: Herbal medicineSmall moleculeContrast agentChemical drug
Industry: Biotech

Drug pipeline

1 asset

jinye baidu granule

Unknown

Partnerships

Parent company is Sinopharm/China TCM; no other major partnerships found.

Beyond the preview

Go deeper on Wuhan Zhonglian Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Zhonglian Pharmaceutical.

Explore the full profile